Global Dementia and Movement Disorder Treatment Market 2017-2021

認知症と運動障害治療の世界市場2017-2021

◆タイトル:Global Dementia and Movement Disorder Treatment Market 2017-2021
◆商品コード:IRTNTR13812
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年7月19日
◆ページ数:102
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、認知症と運動障害治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、認知症と運動障害治療の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

認知症とは、脳の進行性変性を特徴とする疾患の総称です。記憶力を弱め、行動、感情、認知能力に影響を及ぼします。認知症は、脳が影響を受けている場所によって分類されます。アルツハイマー型認知症が最も一般的な認知症です。Technavio社は認知症と運動障害治療の世界市場が2017-2021年期間中に年平均4.48%成長すると予測しています。当レポート上に記載されている主な企業は• Allergan• Eisai• Novartis• Teva Pharmaceutical Industries等です。

About Dementia and Movement Disorder Treatment
Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia. Dementia can be classified into different types, based on the parts of brain affected. Among these types, Alzheimer’s disease is the most common type of dementia.

Technavio’s analysts forecast the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global dementia and movement disorder treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Dementia and Movement Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Allergan
• Eisai
• Novartis
• Teva Pharmaceutical Industries

[Other prominent vendors]
• Amgen
• Pfizer
• UCB
• H. Lundbeck
• F. Hoffmann-La Roche
• Eli Lilly

[Market driver]
• Need for disease modifying drugs (DMDs)
• For a full, detailed list, view our report

[Market challenge]
• Social stigma associated with dementia
• For a full, detailed list, view our report

[Market trend]
• Emergence of biomarkers
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Dementia: An overview
• Dementia
• Epidemiology of disease
• Types of dementia
• Medical interventions to treat dementia
• Parkinson’s disease and dementia

PART 06: Movement disorder: An overview
• Movement disorders
• Cause of movement disorders

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Pipeline

PART 09: Segmentation by drug class
• Global DAMD treatment market by MAO inhibitors
• Global DAMD treatment market by AChE inhibitors
• Global DAMD treatment market by glutamate inhibitors
• Global DAMD treatment market by others

PART 10: Geographical segmentation
• DAMD treatment market in Americas
• DAMD treatment market in EMEA
• DAMD treatment market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
• Market drivers
• Market challenges

PART 13: Market trends
• Emergence of biomarkers
• Growth of gene therapy to reverse cognitive decline associated with Alzheimer’s disease
• Advances in biomedical science

PART 14: Vendor landscape
• Competitive scenario

PART 15: Key vendor analysis
• Allergan
• Eisai
• Novartis
• Teva Pharmaceutical Industries
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Functions of brain affected by dementia
Exhibit 02: Types of Alzheimer’s disease
Exhibit 03: Cognitive impairment in dementia
Exhibit 04: Types of dementia
Exhibit 05: Types of dementia by prevalence rate 2006
Exhibit 06: Vendor initiative in DAMD treatment market
Exhibit 07: Types of movement disorders
Exhibit 08: Insufficient movement disorders
Exhibit 09: Excessive movement disorders
Exhibit 10: Cause of movement disorder
Exhibit 11: Market segmentation by drug class 2016
Exhibit 12: Market snapshot: Global DAMD treatment market
Exhibit 13: Global DAMD treatment market 2016-2021 ($ millions)
Exhibit 14: Opportunity analysis of global DAMD treatment market
Exhibit 15: Five forces analysis
Exhibit 16: Pipeline landscape based on number of molecules 2016
Exhibit 17: Alzheimer’s disease: Key clinical trials
Exhibit 18: Huntington’s disease: Key clinical trials
Exhibit 19: Parkinson’s disease: Key clinical trials
Exhibit 20: Global DAMD treatment market by drug class
Exhibit 21: Global DAMD treatment market by drug-class 2016
Exhibit 22: Global DAMD treatment market by MAO inhibitors 2016-2021 ($ millions)
Exhibit 23: Global DAMD treatment market by AChE inhibitors 2016-2021 ($ millions)
Exhibit 24: Global DAMD treatment market by glutamate inhibitors 2016-2021 ($ millions)
Exhibit 25: Global DAMD treatment market by others 2016-2021 ($ millions)
Exhibit 26: Global DAMD treatment market by geography 2016 and 2021
Exhibit 27: Global DAMD treatment market by geography 2016-2021 ($ millions)
Exhibit 28: Global DAMD treatment market by geography 2016-2021
Exhibit 29: DAMD treatment market scenario in different regions
Exhibit 30: Market scenario in Americas
Exhibit 31: DAMD treatment market in Americas 2016-2021 ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: DAMD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: DAMD treatment market in APAC 2016-2021 ($ millions)
Exhibit 36: Prevalence rate of dementia 2006
Exhibit 37: Geriatric population analysis by geography in 2000 and estimates for 2030
Exhibit 38: Death rate per 100,000 in US population due to Alzheimer’s disease 2010-2014
Exhibit 39: Revenue erosion of Aricept after loss of exclusivity
Exhibit 40: Competitive structure analysis of global DAMD treatment market 2016
Exhibit 41: Allergan: Key highlights
Exhibit 42: Allergan: Strength assessment
Exhibit 43: Allergan: Strategy assessment
Exhibit 44: Allergan: Opportunity assessment
Exhibit 45: Eisai: Key highlights
Exhibit 46: Eisai: Strength assessment
Exhibit 47: Eisai: Strategy assessment
Exhibit 48: Eisai: Opportunity assessment
Exhibit 49: Novartis: Key highlights
Exhibit 50: Novartis: Strength assessment
Exhibit 51: Novartis: Strategy assessment
Exhibit 52: Novartis: Opportunity assessment
Exhibit 53: Teva Pharmaceutical Industries: Pipeline molecules for treatment of neurodegenerative disorders
Exhibit 54: Teva Pharmaceutical Industries: Key highlights
Exhibit 55: Teva Pharmaceutical Industries: Strength assessment
Exhibit 56: Teva Pharmaceutical Industries: Strategy assessment
Exhibit 57: Teva Pharmaceutical Industries: Opportunity assessment



【掲載企業】

Allergan, Eisai, Novartis, Teva Pharmaceutical Industries, Amgen, Pfizer, UCB, H. Lundbeck, F. Hoffmann-La Roche, and Eli Lilly.

★調査レポート[認知症と運動障害治療の世界市場2017-2021] (Global Dementia and Movement Disorder Treatment Market 2017-2021 / IRTNTR13812)販売に関する免責事項
[認知症と運動障害治療の世界市場2017-2021] (Global Dementia and Movement Disorder Treatment Market 2017-2021 / IRTNTR13812)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆